Oligomets and SBRT: "Whack a Mole"? - Advanced Prostate...

Advanced Prostate Cancer

22,262 members27,955 posts

Oligomets and SBRT: "Whack a Mole"?

FrankyB4 profile image
5 Replies

"PSMA-PET guided SBRT for oligo-metachronous PCa recurrence in appropriately triaged patients results in excellent local control, low toxicity and over 50% ADT free at 5 years."

See "Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer"

ro-journal.biomedcentral.co...

“If PSMA PET–CT imaging is positive without conventional correlates that would have

been independently seen on CT or [99mTc]Tc-MTD bone scintigraphy, there may be a knee

jerk reaction to label them as metastatic in the conventional sense. Then clinicians will be

considering agents approved in the metastatic castration sensitive prostate cancer (mCSPC)

such as docetaxel, apalutamide, enzalutamide, or abiraterone.

Understanding the natural history of BCR based on existing data should be used to

inform clinicians about their management decisions in patients who have conventional

imaging devoid of metastatic disease despite PSMA scan findings.

However, if conventional imaging and PSMA PET–CT imaging results are conflicting, interpreting

these results with the knowledge of retrospective studies will be required until prospective

evidence is available to prevent overtreatment and optimize patient care. Upon reviewing

existing data, it becomes more evident that caution should be used when labeling PSMA

positive patients as equivalent to mCSPC and equating them to populations in mCSPC

trials, when it is very likely that the indolent nature of recurrent disease may not be as

impacted from treatment intensification of ADT-based combinations. Deploying such ADT

combinations earlier may have more ambiguous net benefits to patients when weighed

against the toxicity of such regimens which may need to be administered for a decade or

more in some cases.”

See "The Continuum of Metastatic Prostate Cancer: Interpreting PSMA PET Findings in Recurrent Prostate Cancer."

pubmed.ncbi.nlm.nih.gov/353...

Written by
FrankyB4 profile image
FrankyB4
To view profiles and participate in discussions please or .
Read more about...
5 Replies
GP24 profile image
GP24

In the first study 50% of patients did not start with ADT within 5 years after radiation. However, "with median time to BF of 1.1 years." So the median of the patients had biochemical failure, i.e. PSA over 2.0 ng/ml, within 1.1 years.

FrankyB4 profile image
FrankyB4 in reply toGP24

Yes, but 32% of the patients had "further curative-intent radiation following their first BF after SBRT, including subsequent SBRT.

GP24 profile image
GP24 in reply toFrankyB4

Here is a study about repeated SBRT radiation of mets:

ro-journal.biomedcentral.co...

As you can see, sometimes the new mets grow at places where they cannot be radiated.

FrankyB4 profile image
FrankyB4 in reply toGP24

That makes sense.

Here is a paper relating to a recurrent oligo patient ( retired doctor) who rejected ADT and has pursued multiple SBRT for the last 11 years utilizing PSMA scans, or their predecessors, each time his PSA rose to locate the target:

Long-Lasting Palliation of Bone Oligometastatic Prostate Cancer After Repeated Stereotactic Body Radiotherapy

pubmed.ncbi.nlm.nih.gov/345...

j-o-h-n profile image
j-o-h-n

FrankyFr

Good Luck, Good Health and Good Humor.

j-o-h-n Wednesday 09/13/2023 6:04 PM DST

Not what you're looking for?

You may also like...

Quo vadis?

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with...
Kuanyin profile image

Xtandi (enzalutamide) +ADT slows metastases in recurrent men

We recently saw that ADT+Erleada (apalutamide) slows progression compared to ADT alone....

Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via PSMA pet scan

" 31.9% were bio-chemically Disease Free (bDFS) at 15 mo. ! ! ! ! ! All patients with...
George71 profile image

68 Ga-PSMA & too much bad news

New Australian study below. About 10 years ago, at the annual medical, my GP told me that he no...
pjoshea13 profile image

The impact of 18F-DCFPyL-PET/CT on the management of patients with recurrent PCa.

Interesting results from a new study below [1]. "66% (226/341) had a PET-directed change in...
pjoshea13 profile image